Literature DB >> 10864205

Tissue factor, osteopontin, alphavbeta3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression.

S Takano1, K Tsuboi, Y Tomono, Y Mitsui, T Nose.   

Abstract

Vascular endothelial growth factor (VEGF) is a potent angiogenic factor in human gliomas. VEGF-induced proteins in endothelial cells, tissue factor (TF), osteopontin (OPN) and alphavbeta3 integrin have been implicated as important molecules by which VEGF promotes angiogenesis in vivo. Sixty-eight gliomas were immunohistochemically stained with TF, VEGF, OPN and alphavbeta3 integrin antibody. Twenty-three tumours, six normal brains and nine glioma cell lines were evaluated for their mRNA expression of VEGF and TF by reverse transcription polymerase chain reaction analysis. The data indicated that TF as well as VEGF was a strong regulator of human glioma angiogenesis. First, TF expression in endothelial cells which was observed in 74% of glioblastomas, 54% of anaplastic astrocytomas and none of low-grade astrocytomas, correlated with the microvascular density of the tumours. Double staining for VEGF and TF demonstrated co-localization of these two proteins in the glioblastoma tissues. Second, there was a correlation between TF and VEGF mRNA expression in the glioma tissues. Third, glioma cell conditioned medium containing a large amount of VEGF up-regulated the TF mRNA expression in human umbilical vein endothelial cells. OPN and alphavbeta3 integrin, were also predominantly observed in the microvasculature of glioblastomas associated with VEGF expression. Microvascular expression of these molecules could be an effective antiangiogenesis target for human gliomas.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10864205      PMCID: PMC2363244          DOI: 10.1054/bjoc.2000.1150

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  33 in total

Review 1.  Angiogenesis.

Authors:  J Folkman; Y Shing
Journal:  J Biol Chem       Date:  1992-06-05       Impact factor: 5.157

2.  Human tissue factor: cDNA sequence and chromosome localization of the gene.

Authors:  E M Scarpati; D Wen; G J Broze; J P Miletich; R R Flandermeyer; N R Siegel; J E Sadler
Journal:  Biochemistry       Date:  1987-08-25       Impact factor: 3.162

3.  AIDS-associated Kaposi's sarcoma cells in culture express vascular endothelial growth factor.

Authors:  K Weindel; D Marmé; H A Weich
Journal:  Biochem Biophys Res Commun       Date:  1992-03-31       Impact factor: 3.575

4.  Regulation of distinct steps of angiogenesis by different angiogenic molecules.

Authors:  R Kumar; J Yoneda; C D Bucana; I J Fidler
Journal:  Int J Oncol       Date:  1998-04       Impact factor: 5.650

5.  Tissue factor-dependent vascular endothelial growth factor production by human fibroblasts in response to activated factor VII.

Authors:  V Ollivier; S Bentolila; J Chabbat; J Hakim; D de Prost
Journal:  Blood       Date:  1998-04-15       Impact factor: 22.113

6.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo.

Authors:  K J Kim; B Li; J Winer; M Armanini; N Gillett; H S Phillips; N Ferrara
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

7.  Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant.

Authors:  B Millauer; L K Shawver; K H Plate; W Risau; A Ullrich
Journal:  Nature       Date:  1994-02-10       Impact factor: 49.962

8.  Evolution of the functional human beta-actin gene and its multi-pseudogene family: conservation of noncoding regions and chromosomal dispersion of pseudogenes.

Authors:  S Y Ng; P Gunning; R Eddy; P Ponte; J Leavitt; T Shows; L Kedes
Journal:  Mol Cell Biol       Date:  1985-10       Impact factor: 4.272

9.  Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.

Authors:  K H Plate; G Breier; H A Weich; W Risau
Journal:  Nature       Date:  1992-10-29       Impact factor: 49.962

10.  Requirement of vascular integrin alpha v beta 3 for angiogenesis.

Authors:  P C Brooks; R A Clark; D A Cheresh
Journal:  Science       Date:  1994-04-22       Impact factor: 47.728

View more
  34 in total

1.  Osteopontin reduced hypoxia-ischemia neonatal brain injury by suppression of apoptosis in a rat pup model.

Authors:  Wanqiu Chen; Qingyi Ma; Hidenori Suzuki; Richard Hartman; Jiping Tang; John H Zhang
Journal:  Stroke       Date:  2011-01-27       Impact factor: 7.914

2.  Association of osteopontin expression with the prognosis of glioma patient: a meta-analysis.

Authors:  Mingfei Zhao; Hangdi Xu; Feng Liang; Jiliang He; Jianmin Zhang
Journal:  Tumour Biol       Date:  2014-09-30

3.  Hypoxia-inducible factor 1α expression is a prognostic biomarker in patients with astrocytic tumors associated with necrosis on MR image.

Authors:  Ryota Mashiko; Shingo Takano; Eiichi Ishikawa; Tetsuya Yamamoto; Kei Nakai; Akira Matsumura
Journal:  J Neurooncol       Date:  2010-07-02       Impact factor: 4.130

4.  The pro-migratory and pro-invasive role of the procoagulant tissue factor in malignant gliomas.

Authors:  Stephan Dützmann; Florian Gessler; Patrick N Harter; Rüdiger Gerlach; Michel Mittelbronn; Volker Seifert; Donat Kögel
Journal:  Cell Adh Migr       Date:  2010 Oct-Dec       Impact factor: 3.405

Review 5.  The hemostatic system and angiogenesis in malignancy.

Authors:  M Z Wojtukiewicz; E Sierko; P Klement; J Rak
Journal:  Neoplasia       Date:  2001 Sep-Oct       Impact factor: 5.715

6.  Tissue factor expression provokes escape from tumor dormancy and leads to genomic alterations.

Authors:  Nathalie Magnus; Delphine Garnier; Brian Meehan; Serge McGraw; Tae Hoon Lee; Maxime Caron; Guillaume Bourque; Chloe Milsom; Nada Jabado; Jacquetta Trasler; Rafal Pawlinski; Nigel Mackman; Janusz Rak
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-11       Impact factor: 11.205

7.  Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors.

Authors:  Catherine Delbaldo; Eric Raymond; Karina Vera; Luz Hammershaimb; Karen Kaucic; Stéphanie Lozahic; Michel Marty; Sandrine Faivre
Journal:  Invest New Drugs       Date:  2007-09-18       Impact factor: 3.850

8.  Molecular therapeutic targets for glioma angiogenesis.

Authors:  Shingo Takano; Toshiharu Yamashita; Osamu Ohneda
Journal:  J Oncol       Date:  2010-04-18       Impact factor: 4.375

9.  Osteopontin regulates human glioma cell invasiveness and tumor growth in mice.

Authors:  Hsun-Jin Jan; Chin-Cheng Lee; Yung-Luen Shih; Dueng-Yuan Hueng; Hsin-I Ma; Jing-Huei Lai; Hen-Wei Wei; Horng-Mo Lee
Journal:  Neuro Oncol       Date:  2009-12-23       Impact factor: 12.300

10.  PAX6 suppression of glioma angiogenesis and the expression of vascular endothelial growth factor A.

Authors:  Yi-Hong Zhou; Yuanjie Hu; Debra Mayes; Eric Siegel; Jae G Kim; Marlon S Mathews; Nelson Hsu; Daniel Eskander; Ong Yu; Bruce J Tromberg; Mark E Linskey
Journal:  J Neurooncol       Date:  2009-07-19       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.